Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2016; 22(4): 1461-1476
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1461
Metabolic alterations and hepatitis C: From bench to bedside
Ming-Ling Chang
Ming-Ling Chang, Liver Research Center, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
Ming-Ling Chang, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 33302, Taiwan
Author contributions: Chang ML analyzed the literatures and wrote the manuscript.
Supported by Grants from the Chang Gung Medical Research Program, No. CMRPG380353, No. CMRPG3B1251, No. CMRPG3B0401, No. CMRPG3B1741, No. CMRPG3B1742 and No. XMRPG3A0521; and the National Science Council, Taiwan, No. 100-2314-B-182-069-, No. 101-2314-B-182-083- and No. 102-2628-B-182-021-MY3.
Conflict-of-interest statement: The author has no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ming-Ling Chang, MD, PhD, Liver Research Center, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, No. 5, Fu Hsing Street, Kuei Shan, Taoyuan 33305, Taiwan. mlchang8210@gmail.com
Telephone: +886-3-3281200-8102 Fax: +886-3-3272236
Received: May 29, 2015
Peer-review started: June 4, 2015
First decision: July 14, 2015
Revised: August 14, 2015
Accepted: October 23, 2015
Article in press: October 26, 2015
Published online: January 28, 2016
Core Tip

Core tip: Hepatitis C virus (HCV) is thought to cause hypolipidemia, hepatic steatosis, insulin resistance, and diabetes. Its life cycle depends on host cholesterol metabolism. HCV core protein and nonstructural protein 5A perturb crucial metabolic pathways. Many cross-sectional studies have demonstrated increased cardiometabolic risks in HCV patients. Utilizing anti-HCV therapy, most cohort studies have demonstrated the favorable effects of HCV clearance in attenuating cardiometabolic risks. Adipose tissue is an important endocrine organ due to its release of adipocytokines, which strongly regulate metabolism. A comprehensive overview of HCV-associated metabolic and adipocytokine alterations, from bench to bedside, is presented in this topic highlight.